Pillars of growth
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
Operatig revenuesin 2022
Sales for the Heparin Division in 2022(+9% vs 2021)
LMWH presence through strategic alliances with international partners
For the third party, own and Investigational drug manufacture
CMO Sales in 2022 (+52% vs 2021)
Porcentage of women on the Boards of Directors
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.